Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). (Q36024656)

11 August 2017

1 reference

title

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). (English)

1 reference

evasion of host immune response

11 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

J M Kim

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

20 May 2016

1 reference

11 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

1492-1504

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

Oncology meets immunology: the cancer-immunity cycle

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Deciphering and reversing tumor immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The STING pathway and the T cell-inflamed tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

T cell exclusion, immune privilege, and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

21 January 2018

The cancer antigenome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Decisions about dendritic cells: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Adenosine receptors in regulation of dendritic cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Molecular mechanisms of T cell co-stimulation and co-inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Transcriptional mechanisms underlying lymphocyte tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The IL-2 cytokine family in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Trafficking of T cells into tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Immunological hallmarks of stromal cells in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Functional significance of the perforin/granzyme cell death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

In search of the 'missing self': MHC molecules and NK cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Proteolytic release of soluble UL16-binding protein 2 from tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Myeloid-derived suppressor cells in cancer: recent progress and prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Transforming growth factor-beta and the immune response: implications for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Cytokine patterns in patients with cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Regulation of immune responses by prostaglandin E2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

A2A adenosine receptor protects tumors from antitumor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Immune responses in interleukin-2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW217

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207108%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference